Quality Assurance, FDA Regulations Li-Anne Rowswell Mufson Quality Assurance, FDA Regulations Li-Anne Rowswell Mufson

Outsourcing Oversight: FDA Form 483

Learn why maintaining rigorous third-party quality management is just as vital to your drug pipeline as the science itself. Read about why the critical operational risks highlighted in the FDA Form 483 Warning Letter are important to be aware of, and what dangerous oversight gaps exist in pharmaceutical outsourcing. 

Read More
FDA Regulations Li-Anne Rowswell Mufson FDA Regulations Li-Anne Rowswell Mufson

Continuous Manufacturing and ICH Q13: Regulatory Readiness at Scale

Guided by the landmark ICH Q13 guidelines,  the global pharmaceutical industry is undergoing a revolutionary shift from traditional batch manufacturing to agile, continuous production systems. Read this Week's Guard Rail to explore the revolutionary shift from traditional batch manufacturing to agile, continuous production systems. 

Read More
FDA Regulations Li-Anne Rowswell Mufson FDA Regulations Li-Anne Rowswell Mufson

ICH Q12: Post-Approval Change Management for Pharmaceutical Product Lifecycle Management

The formalized roll-out of ICH Q12 mechanisms introduces an organized approach to identifying and managing regulatory commitments. This framework allows manufacturers to execute routine modifications under the oversight of their internal Pharmaceutical Quality System (PQS), reducing the burden of prior-approval regulatory filings.

Read More